Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine
Copyright © 2023. The Korean Association of Immunologists..
The continuous emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has provided insights for updating current coronavirus disease 2019 (COVID-19) vaccines. We examined the neutralizing activity of Abs induced by a BA.4/5-containing bivalent mRNA vaccine against Omicron subvariants BN.1 and XBB.1.5. We recruited 40 individuals who had received a monovalent COVID-19 booster dose after a primary series of COVID-19 vaccinations and will be vaccinated with a BA.4/5-containing bivalent vaccine. Sera were collected before vaccination, one month after, and three months after a bivalent booster. Neutralizing Ab (nAb) titers were measured against ancestral SARS-CoV-2 and Omicron subvariants BA.5, BN.1, and XBB.1.5. BA.4/5-containing bivalent vaccination significantly boosted nAb levels against both ancestral SARS-CoV-2 and Omicron subvariants. Participants with a history of SARS-CoV-2 infection had higher nAb titers against all examined strains than the infection-naïve group. NAb titers against BN.1 and XBB.1.5 were lower than those against the ancestral SARS-CoV-2 and BA.5 strains. These results suggest that COVID-19 vaccinations specifically targeting emerging Omicron subvariants, such as XBB.1.5, may be required to ensure better protection against SARS-CoV-2 infection, especially in high-risk groups.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Immune network - 23(2023), 6 vom: 19. Dez., Seite e43 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nham, Eliel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, neutralizing |
|---|
| Anmerkungen: |
Date Revised 09.01.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4110/in.2023.23.e43 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366792156 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366792156 | ||
| 003 | DE-627 | ||
| 005 | 20240114233159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4110/in.2023.23.e43 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1253.xml |
| 035 | |a (DE-627)NLM366792156 | ||
| 035 | |a (NLM)38188597 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nham, Eliel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023. The Korean Association of Immunologists. | ||
| 520 | |a The continuous emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has provided insights for updating current coronavirus disease 2019 (COVID-19) vaccines. We examined the neutralizing activity of Abs induced by a BA.4/5-containing bivalent mRNA vaccine against Omicron subvariants BN.1 and XBB.1.5. We recruited 40 individuals who had received a monovalent COVID-19 booster dose after a primary series of COVID-19 vaccinations and will be vaccinated with a BA.4/5-containing bivalent vaccine. Sera were collected before vaccination, one month after, and three months after a bivalent booster. Neutralizing Ab (nAb) titers were measured against ancestral SARS-CoV-2 and Omicron subvariants BA.5, BN.1, and XBB.1.5. BA.4/5-containing bivalent vaccination significantly boosted nAb levels against both ancestral SARS-CoV-2 and Omicron subvariants. Participants with a history of SARS-CoV-2 infection had higher nAb titers against all examined strains than the infection-naïve group. NAb titers against BN.1 and XBB.1.5 were lower than those against the ancestral SARS-CoV-2 and BA.5 strains. These results suggest that COVID-19 vaccinations specifically targeting emerging Omicron subvariants, such as XBB.1.5, may be required to ensure better protection against SARS-CoV-2 infection, especially in high-risk groups | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antibodies, neutralizing | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccine | |
| 700 | 1 | |a Kim, Jineui |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jungmin |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Heedo |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jeonghun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sohyun |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Jaeuk |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Kyung Taek |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Jin Gu |e verfasserin |4 aut | |
| 700 | 1 | |a Hwang, Soon Young |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Joon Young |e verfasserin |4 aut | |
| 700 | 1 | |a Cheong, Hee Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Woo Joo |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Man-Seong |e verfasserin |4 aut | |
| 700 | 1 | |a Noh, Ji Yun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immune network |d 2009 |g 23(2023), 6 vom: 19. Dez., Seite e43 |w (DE-627)NLM19466144X |x 1598-2629 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:6 |g day:19 |g month:12 |g pages:e43 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4110/in.2023.23.e43 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 6 |b 19 |c 12 |h e43 | ||